Startseite Advances in understanding and treatment of opioid-induced-bowel-dysfunction, opioid-induced-constipation in particular Nordic recommendations based on multi-specialist input
Artikel Öffentlich zugänglich

Advances in understanding and treatment of opioid-induced-bowel-dysfunction, opioid-induced-constipation in particular Nordic recommendations based on multi-specialist input

  • Audun Stubhaug EMAIL logo
Veröffentlicht/Copyright: 1. April 2016
Veröffentlichen auch Sie bei De Gruyter Brill

In this issue of the Scandinavian Journal of Pain Helene Nordahl Christensen and her co-workers [1] and AsbjØrn Mohr Drewes and his co-workers [2] focus on the under-diagnosed, undertreated, and even inappropriately treated adverse effects on the gastrointestinal tract of opioids prescribed for relief of acute and long-lasting pain.

1 Opioids induce gastrointestinal dysfunction (OIBD), constipation in particular, and conventional laxatives may cause additional problems with negative effects on health-related quality of life

Nordahl Christensen et al. [1] with data from an Internet-based follow-up of patients who had been dispensed opioids for non-cancer pain, confirm that a majority of these patients suffer a significant burden of abdominal symptoms from opioid side effects. Their data confirm that there is a high degree of self management of opioid-induced constipation (OIC) with laxatives, and that there is a low degree of satisfaction with laxatives. Such adverse effects of opioids on functions of the gastrointestinal tract and the unsatisfactory self-management with laxatives contribute to a low health-related quality of life among patients with pain-conditions that are treated with opioids.

2 A Nordic multi-specialist working group for increased awareness of OIBD and advice on treatment of OIBD

There is a need for knowledge-based guidelines, or practice-advisory statements, on how to manage OIBD. The report by Asbjorn Mohr Drewes and his Nordic Working Group composed of different specialists with knowledge and expertise in this area, published in this issue of the Scandinavian Journal of Pain [2] is a thorough literature review of all aspects of opioid-induced bowel dysfunction, giving evidence-based guidelines in the form of GRADE-system-statements and recommendations [2].

3 First line treatment for OIBP is laxatives and lifestyle changes

Following more liberal prescription-practice for opioids as part of the management of chronic pain conditions, opioid-induced bowel dysfunction has increased in prevalence. In guidelines for opioid-treatment of chronic pain, information to patients about adverse effects on the gastrointestinal system is included. Mostly patients receive general advice on increasing diet-fibre, as well as “drink extra water and exercise” [3]. Such advice is not always sufficient Therefore, as shown by Nordahl Christensen et al. [1], patients often end up buying laxatives over the counter (OTC). Pharmacists, as well as nurses in hospitals and in nursing homes, by force of habit and long tradition, advise patients to drink lactulose solutions, sometimes adding bisacodyl, senna, polyethylene glycol. Lactulose may increase intestinal gas and bloating, with minor effect on opioid-induced constipation [2]. The effects of more potent laxatives, e.g. pikosulphate, are difficult to predict, causing social anxieties. Patients may end up with periods of severe constipation alternating with periods of forceful bowel movements and diarrhoea [2].

4 Opioid tapering and opioid rotation may help relieve OIBD

To reduce opioid side-effects, opioid tapering should always be considered. There are evidence that certain opioids such as tapentadol, methadone and transdermal fentanyl may improve bowel function compared with some oral mu-opioids [2].

5 Specific treatment of opioid-induced gastrointestinal bowel dysfunction with opioid antagonists

There are opioid-receptors in the enteric nervous system in the walls of the entire gastrointestinal tract [2]. Opioid agonists bind to these receptors and cause a prolongation of transit times, especially in the colon, reduced enteric secretions into and increased absorption of fluids from the gut lumen. Stools become more compact, making defecation difficult, often painful and incomplete [2]. In the upper parts of the gastrointestinal tract, gastric emptying is delayed, causing gastro-oesophageal regurgitation and dysphagia. Sphincter of Oddi contracts causing elevated pressure in the hepatic and pancreatic ducts.

Whereas potent laxatives can counteract constipation, they do not have any effect on opioid-induced upper gastro-enteric dysfunction. Opioid receptor antagonists can reverse most of these effects, as shown by studies of naloxone given by mouth. If naloxone also enters the central nervous system, analgesic effects of opioids will be abolished and patients on long-term opioid treatment will suddenly experience severe and extremely unpleasant withdrawal symptoms [4]. However, when appropriate doses of naloxone are co-administered in slow-release tablets with oxycodone, parts of the gastrointestinal dysfunctions are prevented without precipitating withdrawal [4,5]. This is due to the almost complete hepatic first-pass elimination of the naloxone that is absorbed from the gastrointestinal tract.

6 Peripherally acting μ-opioid receptor (MOR) antagonists [2] (PAMORAs) prevent opioid-induced bowel dysfunctions in pain patients who need long-term opioid treatment

Peripherally acting μ-opioid receptor (MOR) antagonists (PAMORAs) do not cross the blood-brain-barrier, and do not counteract the analgesic effect of opioids. Treating OIBD with a peripherally acting μ-opioid receptor antagonist is a significant improvement in the treatment of pain patients on opioids. This is also highly relevant for cancer patients with severe pain that requires opioid treatment [6].

There are now several PAMORAs, but only two are marketed in the Nordic countries. Methylnaltrexone (Relistor®) is a quaternary molecule that does not cross the blood-brain-barrier. It is administered by injection and has a fast-onset reversal of opioidagonist-effects in the gastrointestinal tract [2].

Naloxegol (Moventig®) is naloxone to which is attached a long side-chain that makes it impossible for this molecule to get through the blood-brain barrier. It is taken by mouth at a daily dose of 25 mg. Besides reversing the opioid-induced constipation, naloxegol can be expected to diminish opioid-effects on sphincters of the gastrointestinal tract.

Combination treatment with drugs like prucalopride and linaclotide together with irrigation therapy should be considered in difficult cases.

7 Concluding remarks

Better compliance with opioid-prescription and opioid-follow-up strategies [3, 7] will eventually reduce the burden on chronic pain patients from iatrogenic opioid misuse and bowel dysfunction [7]. Conventional laxatives, lifestyle changes and opioid rotation may counteract opioid side-effects on gastrointestinal organs, opioid-induced constipation in particular. Orally administered PAMORAs are representing an important new treatment option. A synthesis of current best evidence is published as recommendations from the group of specialists lead by Abj0rn Mohr Drewes in this issue of the Scandinavian Journal of Pain, based on new knowledge from high quality clinical research [2].


DOIs oforiginalarticles: http://dx.doi.org/10.1016/j.sjpain.2015.12.007, http://dx.doi.org/10.1016/j.sjpain.2015.12.005



Department of Pain Management and Research, Division of Emergencies and Critical Care, Oslo University Hospital, PB 4956 Nydalen, 0424 Oslo, Norway. Tel.:+47 23026161

  1. Conflict of interest: The author has no conflicts of interest.

References

[1] Nordahl Christensen H, Olsson U, From J, Breivik H. Opioid-induced constipation, use of laxatives, and health-related quality of life. Scand J Pain 2016;11:104–10, http://dx.doi.org/10.1016/j.sjpain.2015.12.007.Suche in Google Scholar

[2] Drewes AM, Munkholm P, Simren M, Breivik H, Kongsgaard UE, Hatlebakk JG, Agreus L, Friedrichsen M, Christrup LL. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction—Recommendations of the Nordic Working Group. Scand J Pain 2016;11:111–22, http://dx.doi.org/10.1016Zj.sjpain.2015.12.005.Suche in Google Scholar

[3] Nasjonal faglig veileder bruk av opioider-ved langvarige ikke-kreftrelaterte smerter [National guidelines for opioid treatment of chronic non-cancer pain]. Helsedirektoratet, Oslo, October 23rd, 2014. https://helsedirektoratet.no/retningslinjer/opioider [downloaded 7.2.16].Suche in Google Scholar

[4] Breivik H, Werner MU. Combining an oral opioid-receptoragonist and the antagonist naloxone:a smart drug design that removes some but not all adverse effects ofthe opioid analgesic. Scand J Pain 2014;5:72–4.Suche in Google Scholar

[5] Kaasa T, Romundstad L, Breivik H. New therapeutic principles for adverse effects on upper and lower gastrointestinal tract in patients treated with opioid analgesics. Scand J Pain 2009;1:S12–7.Suche in Google Scholar

[6] Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, Cohen R, Dow L. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20:1420–33, http://dx.doi.org/10.1093/annonc/mdp001. PMID:19244085 Free Article. Suche in Google Scholar

[7] Alford DP. Opioid prescribing for chronic pain-achieving the right balance through education. N Engl J Med 2016;374:301–3.Suche in Google Scholar

Published Online: 2016-04-01
Published in Print: 2016-04-01

© 2016 Scandinavian Association for the Study of Pain

Artikel in diesem Heft

  1. Editorial comment
  2. Psychophysiological effects of threatening a rubber hand that is perceptually embodied in healthy human subjects
  3. Original experimental
  4. A preliminary investigation into psychophysiological effects of threatening a perceptually embodied rubber hand in healthy human participants
  5. Editorial comment
  6. Analysis of C-reactive protein (CRP) levels in pain patients – Can biomarker studies lead to better understanding of the pathophysiology of pain?
  7. Clinical pain research
  8. Serum C-reactive protein levels predict regional brain responses to noxious cold stimulation of the hand in chronic whiplash associated disorders
  9. Editorial comment
  10. Importance of early diagnosis of complex regional pain syndrome (CRPS-1 and CRPS-2): Delayed diagnosis of CRPS is a major problem
  11. Clinical pain research
  12. Delayed diagnosis and worsening of pain following orthopedic surgery in patients with complex regional pain syndrome (CRPS)
  13. Editorial comment
  14. Associative learning mechanisms may trigger increased burden of chronic pain; unlearning and extinguishing learned maladaptive responses should help chronic pain patients
  15. Original experimental
  16. When touch predicts pain: predictive tactile cues modulate perceived intensity of painful stimulation independent of expectancy
  17. Editorial comment
  18. Low back pain among nurses: Common cause of lost days at work and contributing to the worldwide shortage of nurses
  19. Observational study
  20. Pain-related factors associated with lost work days in nurses with low back pain: A cross-sectional study
  21. Editorial comment
  22. Assessment of persistent pelvic pain after hysterectomy: Neuropathic or nociceptive?
  23. Clinical pain research
  24. Characterization of persistent pain after hysterectomy based on gynaecological and sensory examination
  25. Editorial comment
  26. Transmucosal fentanyl for severe cancer pain: Nasal mucosa superior to oral mucosa?
  27. Original experimental
  28. Facilitation of accurate and effective radiation therapy using fentanyl pectin nasal spray (FPNS) to reduce incidental breakthrough pain due to procedure positioning
  29. Editorial comment
  30. Why do we have opioid-receptors in peripheral tissues? Not for relief of pain by opioids
  31. Clinical pain research
  32. Peripheral morphine reduces acute pain in inflamed tissue after third molar extraction: A double-blind, randomized, active-controlled clinical trial
  33. Editorial comment
  34. Chronic pain and psychological distress among long-term social assistance recipients – An intolerable burden on those on the lowest steps of the socioeconomic ladder
  35. Clinical pain research
  36. The co-occurrence of chronic pain and psychological distress and its associations with salient socio-demographic characteristics among long-term social assistance recipients in Norway
  37. Editorial comment
  38. Fifty years on the Visual Analogue Scale (VAS) for pain-intensity is still good for acute pain. But multidimensional assessment is needed for chronic pain
  39. Clinical pain research
  40. Patient reported outcome measures of pain intensity: Do they tell us what we need to know?
  41. Editorial comment
  42. Postoperative pain documentation 30 years after
  43. Topical review
  44. Postoperative pain documentation in a hospital setting: A topical review
  45. Editorial comment
  46. Aspects of pain attitudes and pain beliefs in children: Clinical importance and validity
  47. Observational study
  48. The Survey of Pain Attitudes: A revised version of its pediatric form
  49. Editorial comment
  50. The role of social anxiety in chronic pain and the return-to-work process
  51. Clinical pain research
  52. Social Anxiety, Pain Catastrophizing and Return-To-Work Self-Efficacy in chronic pain: a cross-sectional study
  53. Editorial comment
  54. Advances in understanding and treatment of opioid-induced-bowel-dysfunction, opioid-induced-constipation in particular Nordic recommendations based on multi-specialist input
  55. Topical review
  56. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction–Recommendations of the Nordic Working Group
  57. Observational study
  58. Opioid-induced constipation, use of laxatives, and health-related quality of life
  59. Editorial comment
  60. Migraine headache and bipolar disorders: Common comorbidities
  61. Systematic review
  62. Migraine headache and bipolar disorder comorbidity: A systematic review of the literature and clinical implications
  63. Editorial comment
  64. The role of catastrophizing in the pain–depression relationship
  65. Clinical pain research
  66. The mediating role of catastrophizing in the relationship between pain intensity and depressed mood in older adults with persistent pain: A longitudinal analysis
  67. Announcement
  68. May 26-27, 2016 Scandinavian Association for the Study of Pain, Reykjavik, Iceland May 25, 2016 PhD course
Heruntergeladen am 8.9.2025 von https://www.degruyterbrill.com/document/doi/10.1016/j.sjpain.2016.02.003/html
Button zum nach oben scrollen